The levels of soluble versus insoluble brain aβ distinguish Alzheimer's disease from normal and pathologic aging

Jun Wang, Dennis W Dickson, John Q. Trojanowski, Virginia M Y Lee

Research output: Contribution to journalArticle

417 Citations (Scopus)

Abstract

The abundance and solubility of Aβ peptides are critical determinants of amyloidosis in Alzheimer's disease (AD). Hence, we compared levels of total soluble, insoluble, and total Aβ1-40 and Aβ1-42 in AD brains with those in age-matched normal and pathologic aging brains using a sandwich enzyme-linked immunosorbent assay (ELISA). Since the measurement of Aβ1-40 and Aβ1-42 depends critically on the specificity of the monoclonal antibodies used in the sandwich ELISA, we first demonstrated that each assay is specific for Aβ1-40 or Aβ1-42 and the levels of these peptides are not affected by the amyloid precursor protein in the brain extracts. Thus, this sandwich ELISA enabled us to show that the average levels of total cortical soluble and insoluble Aβ1-40 and Aβ1-42 were highest in AD, lowest in normal aging, and intermediate in pathologic aging. Remarkably, the average levels of insoluble Aβ1-40 were increased 20-fold while the average levels of insoluble Aβ1-42 were increased only 2-fold in the AD brains compared to pathologic aging brains. Further, the soluble pools of Aβ1-40 and Aβ1-42 were the largest fractions of total Aβ in the normal brain (i.e., 50 and 23%, respectively), but they were the smallest in the AD brain (i.e., 2.7 and 0.7%, respectively) and intermediate (i.e., 8 and 0.8%, respectively) in pathologic aging brains. Thus, our data suggest that pathologic aging is a transition state between normal aging and AD. More importantly, our findings imply that a progressive shift of brain Aβ1-40 and Aβ1-42 from soluble to insoluble pools and a profound increase in the levels of insoluble Aβ1-40 plays mechanistic roles in the onset and/or progression of AD.

Original languageEnglish (US)
Pages (from-to)328-337
Number of pages10
JournalExperimental Neurology
Volume158
Issue number2
DOIs
StatePublished - Aug 1999

Fingerprint

Alzheimer Disease
Brain
Enzyme-Linked Immunosorbent Assay
Peptides
Amyloid beta-Protein Precursor
Amyloidosis
Solubility
Monoclonal Antibodies

Keywords

  • Aβ peptide
  • Amyloid plaques
  • Amyloidosis
  • Heterogeneity.

ASJC Scopus subject areas

  • Neurology
  • Neuroscience(all)

Cite this

The levels of soluble versus insoluble brain aβ distinguish Alzheimer's disease from normal and pathologic aging. / Wang, Jun; Dickson, Dennis W; Trojanowski, John Q.; Lee, Virginia M Y.

In: Experimental Neurology, Vol. 158, No. 2, 08.1999, p. 328-337.

Research output: Contribution to journalArticle

@article{2875ece82326410aa29d5d0a5113e68a,
title = "The levels of soluble versus insoluble brain aβ distinguish Alzheimer's disease from normal and pathologic aging",
abstract = "The abundance and solubility of Aβ peptides are critical determinants of amyloidosis in Alzheimer's disease (AD). Hence, we compared levels of total soluble, insoluble, and total Aβ1-40 and Aβ1-42 in AD brains with those in age-matched normal and pathologic aging brains using a sandwich enzyme-linked immunosorbent assay (ELISA). Since the measurement of Aβ1-40 and Aβ1-42 depends critically on the specificity of the monoclonal antibodies used in the sandwich ELISA, we first demonstrated that each assay is specific for Aβ1-40 or Aβ1-42 and the levels of these peptides are not affected by the amyloid precursor protein in the brain extracts. Thus, this sandwich ELISA enabled us to show that the average levels of total cortical soluble and insoluble Aβ1-40 and Aβ1-42 were highest in AD, lowest in normal aging, and intermediate in pathologic aging. Remarkably, the average levels of insoluble Aβ1-40 were increased 20-fold while the average levels of insoluble Aβ1-42 were increased only 2-fold in the AD brains compared to pathologic aging brains. Further, the soluble pools of Aβ1-40 and Aβ1-42 were the largest fractions of total Aβ in the normal brain (i.e., 50 and 23{\%}, respectively), but they were the smallest in the AD brain (i.e., 2.7 and 0.7{\%}, respectively) and intermediate (i.e., 8 and 0.8{\%}, respectively) in pathologic aging brains. Thus, our data suggest that pathologic aging is a transition state between normal aging and AD. More importantly, our findings imply that a progressive shift of brain Aβ1-40 and Aβ1-42 from soluble to insoluble pools and a profound increase in the levels of insoluble Aβ1-40 plays mechanistic roles in the onset and/or progression of AD.",
keywords = "Aβ peptide, Amyloid plaques, Amyloidosis, Heterogeneity.",
author = "Jun Wang and Dickson, {Dennis W} and Trojanowski, {John Q.} and Lee, {Virginia M Y}",
year = "1999",
month = "8",
doi = "10.1006/exnr.1999.7085",
language = "English (US)",
volume = "158",
pages = "328--337",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - The levels of soluble versus insoluble brain aβ distinguish Alzheimer's disease from normal and pathologic aging

AU - Wang, Jun

AU - Dickson, Dennis W

AU - Trojanowski, John Q.

AU - Lee, Virginia M Y

PY - 1999/8

Y1 - 1999/8

N2 - The abundance and solubility of Aβ peptides are critical determinants of amyloidosis in Alzheimer's disease (AD). Hence, we compared levels of total soluble, insoluble, and total Aβ1-40 and Aβ1-42 in AD brains with those in age-matched normal and pathologic aging brains using a sandwich enzyme-linked immunosorbent assay (ELISA). Since the measurement of Aβ1-40 and Aβ1-42 depends critically on the specificity of the monoclonal antibodies used in the sandwich ELISA, we first demonstrated that each assay is specific for Aβ1-40 or Aβ1-42 and the levels of these peptides are not affected by the amyloid precursor protein in the brain extracts. Thus, this sandwich ELISA enabled us to show that the average levels of total cortical soluble and insoluble Aβ1-40 and Aβ1-42 were highest in AD, lowest in normal aging, and intermediate in pathologic aging. Remarkably, the average levels of insoluble Aβ1-40 were increased 20-fold while the average levels of insoluble Aβ1-42 were increased only 2-fold in the AD brains compared to pathologic aging brains. Further, the soluble pools of Aβ1-40 and Aβ1-42 were the largest fractions of total Aβ in the normal brain (i.e., 50 and 23%, respectively), but they were the smallest in the AD brain (i.e., 2.7 and 0.7%, respectively) and intermediate (i.e., 8 and 0.8%, respectively) in pathologic aging brains. Thus, our data suggest that pathologic aging is a transition state between normal aging and AD. More importantly, our findings imply that a progressive shift of brain Aβ1-40 and Aβ1-42 from soluble to insoluble pools and a profound increase in the levels of insoluble Aβ1-40 plays mechanistic roles in the onset and/or progression of AD.

AB - The abundance and solubility of Aβ peptides are critical determinants of amyloidosis in Alzheimer's disease (AD). Hence, we compared levels of total soluble, insoluble, and total Aβ1-40 and Aβ1-42 in AD brains with those in age-matched normal and pathologic aging brains using a sandwich enzyme-linked immunosorbent assay (ELISA). Since the measurement of Aβ1-40 and Aβ1-42 depends critically on the specificity of the monoclonal antibodies used in the sandwich ELISA, we first demonstrated that each assay is specific for Aβ1-40 or Aβ1-42 and the levels of these peptides are not affected by the amyloid precursor protein in the brain extracts. Thus, this sandwich ELISA enabled us to show that the average levels of total cortical soluble and insoluble Aβ1-40 and Aβ1-42 were highest in AD, lowest in normal aging, and intermediate in pathologic aging. Remarkably, the average levels of insoluble Aβ1-40 were increased 20-fold while the average levels of insoluble Aβ1-42 were increased only 2-fold in the AD brains compared to pathologic aging brains. Further, the soluble pools of Aβ1-40 and Aβ1-42 were the largest fractions of total Aβ in the normal brain (i.e., 50 and 23%, respectively), but they were the smallest in the AD brain (i.e., 2.7 and 0.7%, respectively) and intermediate (i.e., 8 and 0.8%, respectively) in pathologic aging brains. Thus, our data suggest that pathologic aging is a transition state between normal aging and AD. More importantly, our findings imply that a progressive shift of brain Aβ1-40 and Aβ1-42 from soluble to insoluble pools and a profound increase in the levels of insoluble Aβ1-40 plays mechanistic roles in the onset and/or progression of AD.

KW - Aβ peptide

KW - Amyloid plaques

KW - Amyloidosis

KW - Heterogeneity.

UR - http://www.scopus.com/inward/record.url?scp=0032837741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032837741&partnerID=8YFLogxK

U2 - 10.1006/exnr.1999.7085

DO - 10.1006/exnr.1999.7085

M3 - Article

C2 - 10415140

AN - SCOPUS:0032837741

VL - 158

SP - 328

EP - 337

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -